Tyrel Somers, MD
Family Medicine · Russell, KSNPI 1174879936
Payments from drug & device makers
Across 133 payments — averaging $18.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$312
- AbbVie$291
- Sunovion Pharmaceuticals Inc.$235
- Sumitomo Pharma America, Inc.$187
- Mylan Specialty L.p.$139
- Astellas Pharma US Inc$127
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,32996%
- Education$1004%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 18 | $312 |
| AbbVie | 17 | $291 |
| Sunovion Pharmaceuticals Inc. | 16 | $235 |
| Sumitomo Pharma America, Inc. | 9 | $187 |
| Mylan Specialty L.p. | 8 | $139 |
| Astellas Pharma US Inc | 4 | $127 |
| Novartis | 6 | $127 |
| Dexcom, Inc. | 6 | $118 |
| Lilly USA, LLC | 7 | $105 |
| Otsuka America Pharmaceutical, Inc. | 4 | $79 |
| Johnson & Johnson | 5 | $79 |
| Insulet Corporation | 3 | $77 |
| Urgo Medical North America, LLC | 1 | $73 |
| Merck | 1 | $54 |
| Pfizer | 4 | $50 |
| Boehringer Ingelheim | 3 | $49 |
| AstraZeneca | 3 | $45 |
| Phathom Pharmaceuticals, Inc. | 3 | $43 |
| Axsome Therapeutics, Inc. | 2 | $30 |
| Novo Nordisk | 2 | $29 |
| Electromed, Inc. | 2 | $26 |
| KCI USA, Inc. | 1 | $24 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| Kerecis Limited | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $13 |
How this compares
$2,429 in reported general payments places this provider in the 75th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 407 | $201,130 |
| IngrezzaValbenazine Tosylate | 12 | $84,618 |
| Humira PenAdalimumab | 11 | $77,597 |
| OzempicSemaglutide | 64 | $66,266 |
| MyrbetriqMirabegron | 93 | $44,628 |
| TrulicityDulaglutide | 40 | $39,027 |
| XareltoRivaroxaban | 56 | $35,565 |
| JardianceEmpagliflozin | 50 | $33,612 |
| FarxigaDapagliflozin Propanediol | 47 | $25,875 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $21,527 |
| JanuviaSitagliptin Phosphate | 37 | $20,954 |
| GemtesaVibegron | 45 | $20,588 |
| MounjaroTirzepatide | 19 | $19,700 |
| Tresiba Flextouch U-100Insulin Degludec | 34 | $19,307 |
| Xtampza ErOxycodone Myristate | 39 | $18,184 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $50 | $213,701447 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $21 | $84,61812 claims |
| Novo NordiskOzempic, Rybelsus | $29 | $82,67881 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $105 | $58,72759 claims |
| Astellas Pharma US IncMyrbetriq | $127 | $44,62893 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Bevespi Aerosphere | $45 | $39,85071 claims |
| Johnson & JohnsonXarelto | $79 | $35,56556 claims |
| Boehringer IngelheimJardiance | $49 | $33,61250 claims |
| MerckJanuvia, Dulera | $54 | $28,93353 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $187 | $20,58845 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $235 | $17,35313 claims |
| AbbVieLinzess | $291 | $6,51012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Russell
- Terry PolingWichita$24.2M
- Richard GloverNewton$19.6M
- Daniel DickersonLenexa$13.6M
- Patrick YaoOlathe$11.7M
- Michael RauschAugusta$8.1M
- Terry KleinWichita$5.9M
- Richard EgelhofWichita$4.1M
- Thomas KleinWichita$3.4M
- Troy HoldemanNewton$3.2M
- Stacy SlechtaNewton$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.